‘We’ll look back and say that this was a bargain.’ Takeda reveals first data from its $4 billion autoimmune disease pill


In an intermediate-stage clinical study of 259 people with moderate-to-severe plaque psoriasis, the highest dose of the daily pill completely cleared itchy and painful patches of skin in one-third of the patients after 12 weeks. “We’re offering the potential for a functional cure,” Andrew Plump, Takeda’s president of research and development, said in an interview.
Doctors and…

This story appeared on bostonglobe.com, 2023-03-18.
The Web's Most Comprehensive Business News Site. Free to Use →